Moreover, the use of rituximab in the R-CHOP regimen for lymphoma, where anti-CD20-mediated B-cell depletion has a synergistic effect with PD-1 blockers to promote cytotoxic T-lymphocyte activation, may have increased CIP risk (8, 9). Here, PDCD1 is linked to lymphoma.